Bimal Shah

Director/Board Member presso ANEBULO PHARMACEUTICALS, INC.

48 anni

Health Technology

Consumer Services

Profilo

Bimal R.
Shah currently works at Anebulo Pharmaceuticals, Inc., as Independent Director from 2023 and Allos Therapeutics, Inc., as Chief Financial Officer & Treasurer from 2012.
Mr. Shah also formerly worked at Spectrum Pharmaceuticals, Inc., as Vice President-Corporate & Business Development from 2013 to 2021.
Mr. Shah received his undergraduate degree, graduate degree, and Masters Business Admin degree from Stanford University.

Posizioni attive di Bimal Shah

Società	Posizione	Inizio
ANEBULO PHARMACEUTICALS, INC.	Director/Board Member	05/10/2023
Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	Director of Finance/CFO	05/09/2012

Tutte le posizioni attive di Bimal Shah

Precedenti posizioni note di Bimal Shah

Società	Posizione	Fine
SPECTRUM PHARMACEUTICALS, INC.	Corporate Officer/Principal	01/01/2021

Vedi nel dettaglio l'esperienza di Bimal Shah

Formazione di Bimal Shah

Stanford University

Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Bimal Shah

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
SPECTRUM PHARMACEUTICALS, INC.	Health Technology
ANEBULO PHARMACEUTICALS, INC.	Health Technology

Aziende private	1
Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	Health Technology